Sarepta Therapeutics, Inc. (SRPT): Price and Financial Metrics

Sarepta Therapeutics, Inc. (SRPT)

Today's Latest Price: $135.91 USD

5.58 (-3.94%)

Updated Oct 30 4:15pm

Add SRPT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

SRPT Stock Summary

  • With a one year PEG ratio of 344.67, Sarepta Therapeutics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 90.36% of US stocks.
  • Price to trailing twelve month operating cash flow for SRPT is currently 36.92, higher than 90.51% of US stocks with positive operating cash flow.
  • With a price/sales ratio of 23.7, Sarepta Therapeutics Inc has a higher such ratio than 93.36% of stocks in our set.
  • Stocks that are quantitatively similar to SRPT, based on their financial statements, market capitalization, and price volatility, are XLRN, FOLD, BBIO, SGMO, and PTCT.
  • SRPT's SEC filings can be seen here. And to visit Sarepta Therapeutics Inc's official web site, go to

SRPT Stock Price Chart Interactive Chart >

Price chart for SRPT

SRPT Price/Volume Stats

Current price $135.91 52-week high $175.00
Prev. close $141.49 52-week low $78.06
Day low $134.14 Volume 723,100
Day high $141.53 Avg. volume 822,308
50-day MA $140.81 Dividend yield N/A
200-day MA $135.29 Market Cap 10.67B

Sarepta Therapeutics, Inc. (SRPT) Company Bio

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The company was founded in 1980 and is based in Cambridge, Massachusetts.

SRPT Latest News Stream

Event/Time News Detail
Loading, please wait...

SRPT Latest Social Stream

Loading social stream, please wait...

View Full SRPT Social Stream

Latest SRPT News From Around the Web

Below are the latest news stories about Sarepta Therapeutics Inc that investors may wish to consider to help them evaluate SRPT as an investment opportunity.

Sarapta up 2% on positive gene therapy data in muscular dystrophy (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) perks up 2% premarket on light volume on the heels of updated follow-up data on two of its gene therapy candidates. SRP-

Seeking Alpha | September 28, 2020

Sarepta to use commercial process material for next study of DMD gene therapy SRPO-9001

Sarepta Therapeutics (SRPT) reports that it has received a written response from the FDA's Center for Biologics Evaluation and Research's ((CBER)) Office of Tissues and Advanced Therapies ((OTAT)) concerning its request to use commercial process material for the next clinical trial for SRP-9001, its investigational gene transfer therapy for Duchenne muscular...

Seeking Alpha | September 10, 2020

Sarepta Therapeutics, Inc. (SRPT) Presents at Robert W Baird Global Healthcare Broker Conference Call - (Transcript)

Sarepta Therapeutics, Inc. (SRPT) Robert W Baird Global Healthcare Broker Conference Call September 10, 2020, 14:00 ET Company Participants Ian Estepan - SVP, Corporate Affairs & Chief of Staff Douglas Ingram - President, CEO & Director Conference Call Participants Brian Skorney - Robert W. Baird & Co. Presentation Brian Skorney...

SA Transcripts on Seeking Alpha | September 10, 2020

Cramer Weighs In On Lumentum, American Airlines And More

On CNBC's "Mad Money Lightning Round," Jim Cramer said that Sarepta Therapeutics Inc (NASDAQ: SRPT ) is good and he would own it, but he prefers Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ). Cramer would be careful with Lumentum Holdings Inc (NASDAQ: LITE ) because … Full story available on

Benzinga | August 6, 2020

Sarepta Therapeutics to Announce Second Quarter 2020 Financial Results and Recent Corporate Developments on August 5, 2020

CAMBRIDGE, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases,…

GlobeNewswire | July 29, 2020

Read More 'SRPT' Stories Here

SRPT Price Returns

1-mo -3.98%
3-mo -11.47%
6-mo 14.85%
1-year 53.45%
3-year 175.18%
5-year 429.66%
YTD 5.32%
2019 18.24%
2018 96.14%
2017 102.84%
2016 -28.90%
2015 166.62%

Continue Researching SRPT

Want to see what other sources are saying about Sarepta Therapeutics Inc's financials and stock price? Try the links below:

Sarepta Therapeutics Inc (SRPT) Stock Price | Nasdaq
Sarepta Therapeutics Inc (SRPT) Stock Quote, History and News - Yahoo Finance
Sarepta Therapeutics Inc (SRPT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7654 seconds.